Literature DB >> 24218520

Short-term projection of cancer incidence in Japan using an age-period interaction model with spline smoothing.

Kota Katanoda1, Ken-Ichi Kamo, Kumiko Saika, Tomohiro Matsuda, Akiko Shibata, Ayako Matsuda, Yoshikazu Nishino, Masakazu Hattori, Midori Soda, Akiko Ioka, Tomotaka Sobue, Hiroshi Nishimoto.   

Abstract

OBJECTIVE: In Japan, population-based cancer incidence data are reported several years behind the latest year of cancer mortality data. To bridge this gap, we aimed to determine a short-term projection method for cancer incidence.
METHODS: Data between 1985 and 2007 were obtained from the population-based cancer registries in four prefectures (Miyagi, Yamagata, Fukui and Nagasaki). Three projection models were examined: generalized linear model with age and period (A + P linear); generalized linear model with age, period and their interactions (A*P linear); and generalized additive model with age, period and their interactions smoothed by spline (A*P spline). We performed a 5-year projection for the years 2000 and 2005, based on the data of 1985-95 and 1985-2000, respectively. Seven cancer sites (stomach, liver, colorectal, lung, female breast, cervix uteri and prostate) and all cancers combined were analyzed. The accuracy of projection was evaluated by whether each observed number fell within the 95% confidence interval of the projected number.
RESULTS: The A*P spline model accurately projected 8 of 13 cancer site-sex combinations, whereas the number of site-sex combinations of accurate projection was 2 and 6 for A + P linear and A*P linear models, respectively. For liver and colorectal cancers, the A*P spline model alone performed accurate projections; the relative differences between projected and observed numbers of cancer incidence ranged between -0.4 and +10.9% for the A*P spline, and between +7.4 and +37.6% for the other two models. All three models failed to project sudden increases in prostate cancer between 2000 and 2005.
CONCLUSIONS: The A*P spline model is a candidate method for the projection of cancer incidence in Japan. However, we need a continuous validation for prostate cancer.

Entities:  

Keywords:  age-period model; age-period-cohort model; cancer incidence; short-term projection

Mesh:

Year:  2013        PMID: 24218520     DOI: 10.1093/jjco/hyt163

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  14 in total

1.  Current condition of genetic medicine for hereditary breast cancer.

Authors:  Hiroko Terui-Kohbata; Masayuki Yoshida
Journal:  Mol Clin Oncol       Date:  2017-05-12

2.  Burden of cancer attributable to modifiable factors in Japan in 2015.

Authors:  Manami Inoue; Mayo Hirabayashi; Sarah Krull Abe; Kota Katanoda; Norie Sawada; Yingsong Lin; Junko Ishihara; Ribeka Takachi; Chisato Nagata; Eiko Saito; Atsushi Goto; Kayo Ueda; Junko Tanaka; Megumi Hori; Tomohiro Matsuda
Journal:  Glob Health Med       Date:  2022-02-28

3.  Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel.

Authors:  Wataru Izumo; Ryota Higuchi; Toru Furukawa; Takehisa Yazawa; Shuichiro Uemura; Yutaro Matsunaga; Masahiro Shiihara; Masakazu Yamamoto
Journal:  Cancer Diagn Progn       Date:  2021-11-03

4.  Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan.

Authors:  Momoko Tsuda; Masahiro Asaka; Mototsugu Kato; Rumiko Matsushima; Kenji Fujimori; Kozo Akino; Shogo Kikuchi; Yingsong Lin; Naoya Sakamoto
Journal:  Helicobacter       Date:  2017-08-03       Impact factor: 5.753

5.  Urinary Polyamine Biomarker Panels with Machine-Learning Differentiated Colorectal Cancers, Benign Disease, and Healthy Controls.

Authors:  Tetsushi Nakajima; Kenji Katsumata; Hiroshi Kuwabara; Ryoko Soya; Masanobu Enomoto; Tetsuo Ishizaki; Akihiko Tsuchida; Masayo Mori; Kana Hiwatari; Tomoyoshi Soga; Masaru Tomita; Masahiro Sugimoto
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

6.  Emotional Responses to Persistent Chemotherapy-induced Peripheral Neuropathy Experienced by Patients with Colorectal Cancer in Japan.

Authors:  Kiyoko Kanda; Keiko Fujimoto; Ayumi Kyota
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Jul-Sep

7.  Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan.

Authors:  Hiroshi Isobe; Kiyoshi Mori; Koichi Minato; Hideki Katsura; Kazuko Taniguchi; Ashwini Arunachalam; Smita Kothari; Xiting Cao; Terufumi Kato
Journal:  Lung Cancer (Auckl)       Date:  2017-10-24

8.  A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).

Authors:  Tetsuji Terazawa; Jin Matsuyama; Masahiro Goto; Ryohei Kawabata; Shunji Endo; Motohiro Imano; Shoichiro Fujita; Yusuke Akamaru; Hirokazu Taniguchi; Mitsutoshi Tatsumi; Sang-Woong Lee; Yoshitaka Kurisu; Hisato Kawakami; Yukinori Kurokawa; Toshio Shimokawa; Daisuke Sakai; Takeshi Kato; Kazumasa Fujitani; Taroh Satoh
Journal:  Oncologist       Date:  2019-09-30

9.  Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Authors:  Yoko Yamada; Nobuaki Matsubara; Ken-Ichi Tabata; Takefumi Satoh; Naoto Kamiya; Hiroyoshi Suzuki; Takashi Kawahara; Hiroji Uemura; Akihiro Yano; Satoru Kawakami
Journal:  BMC Res Notes       Date:  2016-10-18

10.  Ki-67 labeling index as a prognostic marker in advanced stomach cancer.

Authors:  Sang Hyuk Seo; Kwang Hee Kim; Sang Hoon Oh; Yunseon Choi; Ki Jung Ahn; Ji Young Lee; Sang Min Lee; Jisun Park; Woo Gyeong Kim
Journal:  Ann Surg Treat Res       Date:  2018-12-26       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.